Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Jul 16, 2023 12:32pm
221 Views
Post# 35543207

RE:AI

RE:AIThere is some truth in what you are saying - in general.
AI will make inroads and it will have success.

But ...

If certain mechanisms really aren't understood and they still need to be determined, there is no promise that AI will have the answer.

Maybe AI takes the thought process in a variety of new directions but at this point, you still need to ...
1.  ask relevant questions regarding the drugs you are trying to develop
2.  validation is still needed in the lab
3.  then AI needs to take you in the right direction to further as the hard questions and  back into additional validations

One day, AI just may be set-up to handle all these steps and take drugs to succes.  First - the easier problems - then the harder problems and eventually the most difficult of all problems.

When it comes to H2S, the problem is still very difficult and AI isn't there.  It's like trying solve the question of God, with proof.  Like trying to explain the beginning of time, with proof.

----------------------

So, for now, AI isn't our problem.

Our problem is all about drug design for specific (assumed) opportunities where safety (above all else) leads the charge.  The schedule is important - but - it plays second fiddle to overall safety.  Even then, AI isn't going to solve blue ocean drug problems in the near future.  Not in our field.

Right path - right plan - safety first.

Just hoping that investors never use AI properly because stupidity (above all else) is what gives the little guy a chance to explore ... to find treasures.  Then again, asking the wrong questions or going down the wrong paths can take this exploration to its death-bed.

So exciting !

<< Previous
Bullboard Posts
Next >>